P08913
PR
Gene name |
ADRA2A |
Protein name |
Alpha-2A adrenergic receptor |
Names |
Alpha-2 adrenergic receptor subtype C10, Alpha-2A adrenoreceptor, Alpha-2A adrenoceptor, Alpha-2AAR |
Species |
Homo sapiens (Human) |
KEGG Pathway |
hsa:150 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
14 structures for P08913
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 1HLL | NMR | - | A | 133-164 | PDB |
| 1HO9 | NMR | - | A | 133-164 | PDB |
| 1HOD | NMR | - | A | 133-164 | PDB |
| 1HOF | NMR | - | A | 133-164 | PDB |
| 6K42 | EM | 410 A | R | 37-44 | PDB |
| 6KUX | X-ray | 270 A | A | 35-460 | PDB |
| 6KUY | X-ray | 320 A | A | 35-460 | PDB |
| 7EJ0 | EM | 320 A | R | 1-465 | PDB |
| 7EJ8 | EM | 300 A | R | 1-465 | PDB |
| 7EJA | EM | 360 A | R | 1-465 | PDB |
| 7EJK | EM | 340 A | R | 1-465 | PDB |
| 7W6P | EM | 347 A | R | 1-465 | PDB |
| 7W7E | EM | 340 A | R | 1-465 | PDB |
| AF-P08913-F1 | Predicted | AlphaFoldDB |
425 variants for P08913
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
|
CA213922314 rs1017263426 |
2 | F>Y | No |
ClinGen TOPMed gnomAD |
|
|
rs201376588 CA5689842 |
3 | R>C | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA378523607 rs1170097103 |
4 | Q>* | No |
ClinGen gnomAD |
|
| TCGA novel | 5 | E>* | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs781303745 CA5689843 |
5 | E>D | No |
ClinGen ExAC gnomAD |
|
|
CA5689844 rs745988173 |
6 | Q>L | No |
ClinGen ExAC gnomAD |
|
|
CA213922315 rs929408642 |
7 | P>L | No |
ClinGen TOPMed |
|
|
CA378523646 rs1312995789 |
10 | E>K | No |
ClinGen TOPMed gnomAD |
|
|
CA378523657 rs1339221375 |
11 | G>D | No |
ClinGen gnomAD |
|
|
CA213922316 rs1046455356 |
12 | S>N | No |
ClinGen TOPMed |
|
|
CA378523665 rs1271796267 |
12 | S>R | No |
ClinGen gnomAD |
|
|
CA5689845 rs770095627 |
13 | F>L | No |
ClinGen ExAC gnomAD |
|
|
CA378523676 rs1218485170 |
14 | A>S | No |
ClinGen gnomAD |
|
|
rs775887911 CA5689846 |
15 | P>L | No |
ClinGen ExAC gnomAD |
|
|
CA378523697 rs1262595559 |
17 | G>D | No |
ClinGen gnomAD |
|
|
rs1211818028 CA378523694 |
17 | G>S | No |
ClinGen TOPMed gnomAD |
|
|
CA378523705 rs1445294584 |
18 | S>F | No |
ClinGen gnomAD |
|
|
CA5689848 rs772008603 |
20 | Q>K | No |
ClinGen ExAC gnomAD |
|
|
rs772940005 CA5689849 |
21 | P>L | No |
ClinGen ExAC gnomAD |
|
|
CA213922317 rs938518561 |
22 | D>N | No |
ClinGen TOPMed gnomAD |
|
|
CA378523732 rs1434964078 |
23 | A>S | No |
ClinGen TOPMed |
|
|
CA378523730 rs1434964078 |
23 | A>T | No |
ClinGen TOPMed |
|
|
rs766274296 CA5689851 |
23 | A>V | No |
ClinGen ExAC gnomAD |
|
|
rs1319699564 CA378523737 |
24 | G>C | No |
ClinGen TOPMed gnomAD |
|
|
CA378523746 rs1368766249 |
25 | N>S | No |
ClinGen TOPMed |
|
|
CA5689854 rs764799619 |
26 | A>G | No |
ClinGen ExAC gnomAD |
|
|
CA378523751 rs1589531496 |
26 | A>S | No |
ClinGen Ensembl |
|
|
rs764512237 CA378523780 |
30 | G>A | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA5689857 rs764512237 |
30 | G>E | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA213922318 rs758103040 CA5689856 |
30 | G>R | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs758103040 CA378523779 |
30 | G>W | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1011212429 CA213922319 |
31 | T>N | No |
ClinGen TOPMed |
|
|
CA213922321 rs753177273 |
32 | E>K | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs753177273 CA5689860 |
32 | E>Q | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1207024336 CA378523790 |
32 | E>V | No |
ClinGen gnomAD |
|
|
CA378523795 rs1285010032 |
33 | A>S | No |
ClinGen gnomAD |
|
|
rs1451568699 CA378523796 |
33 | A>V | No |
ClinGen gnomAD |
|
|
CA378523805 rs1564745326 |
34 | P>L | No |
ClinGen Ensembl |
|
|
rs1255304040 CA378523800 |
34 | P>T | No |
ClinGen gnomAD |
|
|
CA213922322 rs999050821 |
35 | G>A | No |
ClinGen TOPMed gnomAD |
|
|
CA378523811 rs999050821 |
35 | G>E | No |
ClinGen TOPMed gnomAD |
|
|
rs1178408507 CA378523808 |
35 | G>R | No |
ClinGen gnomAD |
|
|
rs1178408507 CA378523809 |
35 | G>W | No |
ClinGen gnomAD |
|
| rs1554870245 | 36 | G>A | Variant assessed as Somatic; 0.0001986 impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA213922324 rs780365245 |
36 | G>D | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1030075261 CA213922323 |
36 | G>S | No |
ClinGen TOPMed gnomAD |
|
|
CA5689863 rs780365245 |
36 | G>V | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs13306143 CA5689864 |
37 | G>S | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs768798747 CA5689865 |
39 | R>G | No |
ClinGen ExAC gnomAD |
|
|
CA5689866 rs539511086 |
39 | R>Q | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
rs768798747 CA378523843 |
39 | R>W | No |
ClinGen ExAC gnomAD |
|
|
rs1800034 CA5689868 |
40 | A>G | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA378523858 rs1589531570 |
41 | T>P | No |
ClinGen Ensembl |
|
|
CA378523865 rs1241405492 |
42 | P>T | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
CA378523895 rs1280233332 |
43 | Y>* | No |
ClinGen TOPMed gnomAD |
|
|
CA378523917 rs1212376235 |
45 | L>P | No |
ClinGen TOPMed gnomAD |
|
|
rs1332395859 CA378523919 |
46 | Q>K | No |
ClinGen TOPMed |
|
|
CA5689870 rs758985542 |
46 | Q>L | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs758985542 CA378523923 |
46 | Q>P | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA213922329 rs973635708 |
47 | V>M | No |
ClinGen TOPMed gnomAD |
|
|
CA5689871 rs764711080 |
48 | T>M | No |
ClinGen ExAC gnomAD |
|
|
CA378523967 rs1416968964 |
50 | T>A | No |
ClinGen gnomAD |
|
|
CA378523974 rs1183473814 |
50 | T>M | No |
ClinGen gnomAD |
|
|
CA5689873 rs762565315 |
52 | V>G | No |
ClinGen ExAC gnomAD |
|
|
rs1363892145 CA378523993 |
52 | V>L | No |
ClinGen gnomAD |
|
|
rs751907762 CA5689875 |
54 | L>V | No |
ClinGen ExAC gnomAD |
|
|
CA378524040 rs1461868679 |
55 | A>S | No |
ClinGen gnomAD |
|
|
CA378524044 rs1330465178 |
55 | A>V | No |
ClinGen gnomAD |
|
|
rs533963725 CA5689877 |
56 | G>S | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
CA5689878 rs750980945 |
56 | G>V | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA378524082 rs1235422960 |
58 | L>P | No |
ClinGen TOPMed |
|
|
rs376175216 TCGA novel CA5689881 |
59 | M>I | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
NCI-TCGA ClinGen ESP ExAC gnomAD |
|
rs1336158161 CA378524115 |
61 | L>I | No |
ClinGen TOPMed gnomAD |
|
|
CA213922331 rs928033054 |
63 | V>M | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed |
|
rs755176488 CA5689882 |
64 | F>I | No |
ClinGen ExAC gnomAD |
|
|
rs1327634108 CA378524165 |
65 | G>R | No |
ClinGen TOPMed |
|
|
rs779035240 CA5689883 |
67 | V>M | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA378524204 rs1224440739 |
68 | L>F | No |
ClinGen TOPMed |
|
|
CA378524220 rs1447519480 |
69 | V>I | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed |
|
rs1250876817 CA378524235 |
70 | I>V | No |
ClinGen gnomAD |
|
|
CA5689889 rs745798122 |
71 | I>T | No |
ClinGen ExAC |
|
| TCGA novel | 71 | I>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 72 | A>T | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 72 | A>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs769760628 CA5689890 |
73 | V>G | No |
ClinGen ExAC gnomAD |
|
|
CA378524271 rs1185211608 |
73 | V>M | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
rs774962215 CA5689891 |
75 | T>M | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA378524338 rs1420408033 |
78 | A>S | No |
ClinGen TOPMed |
|
|
CA213922333 rs915734210 |
81 | A>T | No |
ClinGen TOPMed |
|
|
CA5689895 rs762180589 |
81 | A>V | No |
ClinGen ExAC gnomAD |
|
|
rs544890991 CA5689897 |
82 | P>S | No |
ClinGen 1000Genomes ExAC |
|
|
rs767014642 CA5689899 |
83 | Q>P | No |
ClinGen ExAC gnomAD |
|
|
CA5689901 rs33944494 |
84 | N>K | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
CA378524420 rs1314872341 |
84 | N>S | No |
ClinGen gnomAD |
|
|
rs779134972 CA5689902 |
85 | L>F | No |
ClinGen ExAC gnomAD |
|
|
rs752846895 CA5689903 |
85 | L>H | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1228685601 CA378524435 |
87 | L>V | No |
ClinGen TOPMed gnomAD |
|
| TCGA novel | 92 | S>P | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA378524507 rs1318842760 |
93 | A>G | No |
ClinGen TOPMed |
|
|
CA378524511 rs1287731776 |
94 | D>N | No |
ClinGen TOPMed |
|
|
CA5689907 rs367957599 |
97 | V>M | No |
ClinGen ESP ExAC gnomAD |
|
|
CA5689908 rs138797613 |
98 | A>T | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs748769086 CA5689909 |
99 | T>A | No |
ClinGen ExAC gnomAD |
|
|
rs778067962 CA213922335 |
99 | T>R | No |
ClinGen Ensembl |
|
|
rs768064852 CA5689910 |
100 | L>F | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs768064852 CA213922336 |
100 | L>I | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA5689913 rs761368313 |
102 | I>M | No |
ClinGen ExAC gnomAD |
|
|
CA5689914 rs773661515 |
108 | N>H | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs766924854 CA5689916 |
108 | N>K | No |
ClinGen ExAC gnomAD |
|
|
CA5689915 rs761151713 |
108 | N>S | No |
ClinGen ExAC gnomAD |
|
|
rs372220514 CA5689917 |
110 | V>I | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs998498842 CA213922337 |
111 | M>L | No |
ClinGen TOPMed |
|
|
rs1301045683 CA378524763 |
114 | W>* | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
CA378524755 rs1383229337 |
114 | W>R | No |
ClinGen gnomAD |
|
|
CA5689919 COSM537366 rs765223992 |
116 | F>L | lung [Cosmic] | No |
ClinGen cosmic curated ExAC TOPMed gnomAD |
|
rs965756322 CA213922338 |
117 | G>V | No |
ClinGen Ensembl |
|
|
rs1386786229 CA378524814 |
118 | K>E | No |
ClinGen TOPMed |
|
|
rs1282104494 CA378524825 |
118 | K>N | No |
ClinGen gnomAD |
|
|
rs758523920 CA378524832 |
119 | A>S | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs758523920 CA5689922 |
119 | A>T | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs866205234 CA213922339 |
120 | W>* | No |
ClinGen Ensembl |
|
|
CA213922341 rs1026262231 |
121 | C>W | No |
ClinGen TOPMed gnomAD |
|
|
rs777995895 CA5689923 |
123 | I>L | No |
ClinGen ExAC gnomAD |
|
|
rs374866490 CA5689925 |
123 | I>S | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs374866490 CA5689924 |
123 | I>T | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
CA378524908 rs1245471352 |
124 | Y>C | No |
ClinGen TOPMed |
|
|
rs1205593353 CA378524923 |
125 | L>P | No |
ClinGen gnomAD |
|
|
CA5689928 rs749168689 |
126 | A>E | No |
ClinGen ExAC gnomAD |
|
|
CA5689927 rs749168689 COSM914792 |
126 | A>V | Variant assessed as Somatic; 0.0 impact. endometrium [NCI-TCGA, Cosmic] | No |
ClinGen cosmic curated ExAC NCI-TCGA gnomAD |
|
CA213922342 rs909039909 |
129 | V>L | No |
ClinGen Ensembl |
|
| TCGA novel | 129 | V>M | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA378524987 rs1226383620 |
132 | C>S | No |
ClinGen TOPMed |
|
|
CA5689932 rs771808338 |
135 | S>C | No |
ClinGen ExAC gnomAD |
|
|
CA378525012 rs1454775700 |
136 | I>T | No |
ClinGen gnomAD |
|
|
CA378525019 rs1196098168 |
137 | V>A | No |
ClinGen gnomAD |
|
|
CA378525017 rs1174906401 |
137 | V>L | No |
ClinGen Ensembl |
|
|
CA378525057 rs1443650366 |
143 | S>G | No |
ClinGen gnomAD |
|
|
CA5689935 rs771405434 |
143 | S>I | No |
ClinGen ExAC gnomAD |
|
|
rs369222614 CA5689937 |
144 | L>V | No |
ClinGen ESP ExAC gnomAD |
|
| TCGA novel | 145 | D>N | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 146 | R>H | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA378525087 rs1318134917 |
147 | Y>* | No |
ClinGen gnomAD |
|
|
CA378525085 rs1166338005 |
147 | Y>C | No |
ClinGen TOPMed |
|
|
CA378525124 rs1216410475 |
153 | A>T | No |
ClinGen gnomAD |
|
|
rs1272542651 CA378525129 |
153 | A>V | No |
ClinGen gnomAD |
|
|
rs373186564 CA5689939 |
155 | E>K | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA213922344 rs770512793 |
159 | K>R | No |
ClinGen Ensembl |
|
|
rs980881935 CA213922345 |
160 | R>C | No |
ClinGen Ensembl |
|
|
CA378525178 rs1564745516 |
161 | T>A | No |
ClinGen Ensembl |
|
|
CA378525180 rs1368411315 |
161 | T>K | No |
ClinGen TOPMed gnomAD |
|
|
CA5689942 rs146469074 |
163 | R>C | No |
ClinGen ESP ExAC gnomAD |
|
| TCGA novel | 167 | A>T | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA5689943 rs757533221 |
167 | A>V | No |
ClinGen ExAC gnomAD |
|
|
rs1589531789 CA378525241 |
171 | T>P | No |
ClinGen Ensembl |
|
|
CA213922347 rs926679360 |
172 | V>M | No |
ClinGen Ensembl |
|
|
rs766158831 CA5689944 |
173 | W>C | No |
ClinGen ExAC gnomAD |
|
|
CA5689945 rs753708251 |
174 | V>A | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs754851204 CA5689946 |
175 | I>V | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 176 | S>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs778937983 CA5689947 |
176 | S>P | No |
ClinGen ExAC gnomAD |
|
|
CA5689948 rs199783285 |
177 | A>V | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA213922349 rs959479352 |
178 | V>F | No |
ClinGen TOPMed |
|
|
rs746650953 CA5689951 |
181 | F>I | No |
ClinGen ExAC gnomAD |
|
|
rs774567101 CA213922350 |
181 | F>S | No |
ClinGen ExAC gnomAD |
|
|
CA5689952 rs774567101 |
181 | F>Y | No |
ClinGen ExAC gnomAD |
|
|
CA378525326 rs1273594845 |
185 | I>T | No |
ClinGen gnomAD |
|
| TCGA novel | 186 | S>C | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1564745549 CA378525333 |
186 | S>F | No |
ClinGen Ensembl |
|
|
rs746264766 CA5689954 |
187 | I>V | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA378525342 rs1564745557 |
188 | E>Q | No |
ClinGen Ensembl |
|
|
CA378525365 rs1481071032 |
191 | G>S | No |
ClinGen TOPMed gnomAD |
|
|
CA5689959 rs762965708 |
192 | G>C | No |
ClinGen ExAC gnomAD |
|
|
rs561690973 CA5689960 |
192 | G>D | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
CA378525384 rs1390292470 |
194 | G>D | No |
ClinGen TOPMed |
|
|
rs753529817 CA5689964 |
195 | G>D | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA5689963 rs200592713 |
195 | G>R | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
rs200592713 CA5689962 |
195 | G>S | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
rs1355965187 CA378525391 |
196 | P>A | No |
ClinGen TOPMed gnomAD |
|
|
rs754805284 CA5689966 |
196 | P>L | No |
ClinGen ExAC gnomAD |
|
|
CA5689965 rs754805284 |
196 | P>Q | No |
ClinGen ExAC gnomAD |
|
|
CA378525406 rs377089521 |
198 | P>L | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
CA5689968 rs377089521 |
198 | P>Q | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs1431566720 CA378525404 |
198 | P>S | No |
ClinGen TOPMed |
|
|
rs1284779509 CA378525410 |
199 | A>V | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
rs370131502 CA5689971 |
200 | E>K | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
CA5689970 rs370131502 |
200 | E>Q | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs1051407392 CA213922352 |
201 | P>L | No |
ClinGen TOPMed gnomAD |
|
|
CA378525421 rs1589531863 |
201 | P>S | No |
ClinGen Ensembl |
|
|
CA378525424 rs1262239285 |
202 | R>C | No |
ClinGen TOPMed |
|
|
rs550864420 CA5689972 |
202 | R>L | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA378525428 rs550864420 |
202 | R>P | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA5689973 rs746155867 |
204 | E>K | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA TOPMed gnomAD |
|
CA5689974 rs746155867 |
204 | E>Q | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA5689975 rs780345065 |
206 | N>D | No |
ClinGen ExAC gnomAD |
|
|
rs1265977627 CA378525458 |
207 | D>H | No |
ClinGen TOPMed gnomAD |
|
|
CA378525459 rs1265977627 |
207 | D>Y | No |
ClinGen TOPMed gnomAD |
|
|
rs1474699885 CA378525477 |
209 | K>R | No |
ClinGen gnomAD |
|
|
rs1430017825 CA378525520 |
215 | S>* | No |
ClinGen gnomAD |
|
|
CA5689977 rs769192080 |
218 | G>R | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 218 | G>S | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA213922353 rs867166817 |
218 | G>V | No |
ClinGen Ensembl |
|
|
CA378525545 rs1564745605 |
219 | S>Y | No |
ClinGen Ensembl |
|
|
rs1325827838 CA378525566 |
222 | A>S | No |
ClinGen gnomAD |
|
|
rs772117742 CA5689981 |
225 | L>V | No |
ClinGen ExAC gnomAD |
|
|
CA5689983 rs760862867 |
226 | I>S | No |
ClinGen ExAC gnomAD |
|
|
CA5689984 rs200814490 |
228 | I>V | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA378525612 rs1350303464 |
229 | L>Q | No |
ClinGen gnomAD |
|
|
rs200429541 CA213922354 |
230 | V>I | No |
ClinGen Ensembl |
|
|
CA378525627 rs1201155743 |
231 | Y>* | No |
ClinGen gnomAD |
|
|
CA378525630 rs1283608041 |
232 | V>L | No |
ClinGen TOPMed gnomAD |
|
|
rs1283608041 CA378525628 |
232 | V>M | No |
ClinGen TOPMed gnomAD |
|
| TCGA novel | 233 | R>H | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs149350078 CA5689988 |
234 | I>M | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs762958713 CA5689987 |
234 | I>V | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 236 | Q>E | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs751070655 CA5689989 |
239 | K>Q | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs375615894 CA213922355 |
240 | R>H | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
rs375615894 CA378525684 |
240 | R>L | No |
ClinGen gnomAD |
|
|
rs867426803 CA213922356 |
241 | R>H | No |
ClinGen Ensembl |
|
|
rs1455284189 CA378525694 |
242 | T>N | No |
ClinGen gnomAD |
|
|
rs1172690699 CA378525697 |
243 | R>S | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
rs1383559374 CA378525703 |
244 | V>M | No |
ClinGen TOPMed gnomAD |
|
|
CA5689990 rs756797941 |
246 | P>S | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 247 | S>G | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA5689991 rs780653851 |
248 | R>H | No |
ClinGen ExAC gnomAD |
|
|
rs1439968191 CA378525734 |
249 | R>W | No |
ClinGen gnomAD |
|
|
rs1300951908 CA378525741 |
250 | G>D | No |
ClinGen gnomAD |
|
|
rs375697365 CA5689993 |
251 | P>L | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA5689992 rs375697365 |
251 | P>R | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
rs1373517417 CA378525744 |
251 | P>T | No |
ClinGen gnomAD |
|
|
rs1168967848 CA378525761 |
253 | A>V | No |
ClinGen TOPMed gnomAD |
|
|
rs1038798122 CA213922358 |
254 | V>L | No |
ClinGen TOPMed |
|
|
CA5689994 rs780435602 |
256 | A>S | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA378525782 rs1266225906 |
257 | P>L | No |
ClinGen TOPMed |
|
|
rs749705885 CA5689995 |
257 | P>S | No |
ClinGen ExAC gnomAD |
|
|
CA378525800 rs899363921 |
259 | G>A | No |
ClinGen TOPMed |
|
|
CA213922359 rs899363921 |
259 | G>V | No |
ClinGen TOPMed |
|
|
CA378525803 rs1242185410 |
260 | G>S | No |
ClinGen TOPMed |
|
|
rs1315271143 CA378525820 |
261 | T>I | No |
ClinGen TOPMed |
|
|
CA378525836 rs1453916622 |
263 | R>S | No |
ClinGen TOPMed |
|
|
rs1362709671 CA378525847 |
264 | R>W | No |
ClinGen TOPMed gnomAD |
|
|
rs1400599840 CA378525863 |
265 | P>R | No |
ClinGen TOPMed |
|
|
CA378525860 rs1316856892 |
265 | P>S | No |
ClinGen TOPMed |
|
|
rs566589780 CA5689998 |
266 | N>D | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA5689999 VAR_014957 rs1800035 |
266 | N>K | frequency in Caucasians 0.004 and in African-Americans 0.05; 40% increase in agonist-promoted Gi coupling [UniProt] | No |
ClinGen UniProt 1000Genomes ExAC TOPMed dbSNP gnomAD |
|
rs1384921331 CA378525882 |
267 | G>C | No |
ClinGen TOPMed |
|
|
rs773228256 CA5690000 |
267 | G>D | No |
ClinGen ExAC gnomAD |
|
|
CA378525901 rs1365069112 |
269 | G>D | No |
ClinGen TOPMed gnomAD |
|
|
CA213922360 rs1004192709 |
269 | G>S | No |
ClinGen TOPMed |
|
|
CA378525923 rs1035053827 |
271 | E>G | No |
ClinGen TOPMed gnomAD |
|
|
CA213922361 rs1035053827 |
271 | E>V | No |
ClinGen TOPMed gnomAD |
|
|
rs1589532006 CA378525931 |
272 | R>G | No |
ClinGen Ensembl |
|
|
CA378525935 rs1387578710 |
272 | R>H | No |
ClinGen TOPMed gnomAD |
|
|
rs1387578710 CA378525938 |
272 | R>L | No |
ClinGen TOPMed gnomAD |
|
|
CA378525982 rs1207591864 |
276 | P>L | No |
ClinGen TOPMed |
|
|
rs990898779 CA213922364 |
277 | G>R | No |
ClinGen TOPMed gnomAD |
|
|
CA378526000 rs1328513309 |
278 | G>D | No |
ClinGen TOPMed gnomAD |
|
|
rs1328513309 CA378526004 |
278 | G>V | No |
ClinGen TOPMed gnomAD |
|
|
CA378526005 rs1334191735 |
279 | A>T | No |
ClinGen gnomAD |
|
|
rs1289034488 CA378526029 |
281 | A>P | No |
ClinGen gnomAD |
|
|
rs1289034488 CA378526028 |
281 | A>T | No |
ClinGen gnomAD |
|
|
CA378526038 rs1334804140 |
282 | E>K | No |
ClinGen gnomAD |
|
|
CA213922366 rs968526462 |
283 | P>L | No |
ClinGen TOPMed |
|
|
CA378526068 rs1264483604 |
285 | P>A | No |
ClinGen TOPMed gnomAD |
|
|
CA378526066 rs1264483604 |
285 | P>T | No |
ClinGen TOPMed gnomAD |
|
|
rs1214982410 CA378526088 |
287 | Q>E | No |
ClinGen gnomAD |
|
| TCGA novel | 287 | Q>K | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA378526111 rs1589532037 |
289 | N>D | No |
ClinGen Ensembl |
|
|
rs1164458352 CA378526114 |
289 | N>S | No |
ClinGen TOPMed |
|
|
rs1275460082 CA378526140 |
291 | A>V | No |
ClinGen TOPMed gnomAD |
|
|
rs1421312390 CA378526147 |
292 | P>H | No |
ClinGen TOPMed gnomAD |
|
|
CA213922369 rs934624217 |
294 | E>D | No |
ClinGen TOPMed |
|
|
CA378526181 rs1589532058 |
296 | A>T | No |
ClinGen Ensembl |
|
| TCGA novel | 296 | A>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA5690003 rs548917756 |
297 | P>S | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
rs1589532071 CA378526218 |
299 | G>E | No |
ClinGen Ensembl |
|
|
CA213922373 rs898875531 CA213922374 |
299 | G>R | No |
ClinGen TOPMed gnomAD |
|
|
rs898875531 CA378526198 |
299 | G>W | No |
ClinGen TOPMed gnomAD |
|
| TCGA novel | 300 | P>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA378526220 rs1183761987 |
300 | P>T | No |
ClinGen gnomAD |
|
|
rs775375141 CA213922375 |
301 | R>C | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs775375141 CA378526230 |
301 | R>G | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA213922376 rs886590597 |
301 | R>H | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed gnomAD |
|
CA5690004 rs775375141 |
301 | R>S | No |
ClinGen ExAC TOPMed gnomAD |
|
| TCGA novel | 302 | D>Y | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA213922377 rs1003840369 |
303 | T>I | No |
ClinGen TOPMed |
|
|
CA378526269 rs1398285143 |
304 | D>E | No |
ClinGen TOPMed |
|
|
CA378526263 rs1410379168 |
304 | D>N | No |
ClinGen TOPMed |
|
|
CA378526273 rs1174185126 |
305 | A>T | No |
ClinGen TOPMed |
|
|
CA378526302 rs1201011841 |
308 | L>V | No |
ClinGen TOPMed |
|
| TCGA novel | 309 | E>K | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1589532097 CA378526368 |
313 | S>T | No |
ClinGen Ensembl |
|
|
CA378526412 rs1468155388 |
316 | H>Y | No |
ClinGen TOPMed |
|
|
rs1369982880 CA378526424 |
317 | A>T | No |
ClinGen gnomAD |
|
|
CA378526459 rs1204711473 |
319 | R>Q | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed |
|
CA378526453 rs1458272935 |
319 | R>W | No |
ClinGen gnomAD |
|
|
rs1438759350 CA378526465 |
320 | P>S | No |
ClinGen TOPMed |
|
|
rs1275506232 CA378526495 |
322 | G>V | No |
ClinGen TOPMed |
|
|
rs1436373474 CA378526503 |
323 | P>H | No |
ClinGen gnomAD |
|
|
CA378526515 rs1308741559 |
324 | R>H | No |
ClinGen TOPMed gnomAD |
|
|
CA378526519 rs1308741559 |
324 | R>L | No |
ClinGen TOPMed gnomAD |
|
|
CA378526510 rs1411829914 |
324 | R>S | No |
ClinGen gnomAD |
|
| TCGA novel | 328 | R>C | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1395809551 CA378526567 |
328 | R>L | No |
ClinGen TOPMed gnomAD |
|
|
rs1354841234 CA378526562 |
328 | R>S | No |
ClinGen gnomAD |
|
|
rs1295721632 CA378526572 |
329 | G>C | No |
ClinGen TOPMed gnomAD |
|
|
CA378526570 rs1295721632 |
329 | G>S | No |
ClinGen TOPMed gnomAD |
|
| TCGA novel | 332 | G>S | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA378526604 rs1335051162 |
332 | G>V | No |
ClinGen TOPMed gnomAD |
|
|
CA378526621 rs1279200008 |
334 | G>S | No |
ClinGen TOPMed |
|
|
CA378526653 rs1443114071 |
337 | R>G | No |
ClinGen TOPMed |
|
|
CA378526656 rs1227214850 |
337 | R>Q | No |
ClinGen gnomAD |
|
|
rs1234618922 CA378526662 |
338 | A>S | No |
ClinGen gnomAD |
|
|
CA378526677 rs1334505469 |
339 | S>N | No |
ClinGen TOPMed |
|
|
CA378526683 rs1564745793 |
339 | S>R | No |
ClinGen Ensembl |
|
|
CA213922380 rs1012164206 |
340 | Q>E | No |
ClinGen TOPMed |
|
|
rs1249942949 CA378526748 |
345 | D>N | No |
ClinGen gnomAD |
|
|
rs1337073911 CA378526794 |
348 | P>R | No |
ClinGen gnomAD |
|
|
rs567331068 CA213922381 |
348 | P>S | No |
ClinGen 1000Genomes |
|
|
rs1206794752 CA378526799 |
349 | R>W | No |
ClinGen TOPMed gnomAD |
|
|
rs1274749299 CA378526830 |
351 | G>E | No |
ClinGen gnomAD |
|
| TCGA novel | 352 | P>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 353 | G>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA378526865 rs1258239544 |
354 | A>E | No |
ClinGen TOPMed gnomAD |
|
|
CA5690005 rs762870842 |
355 | T>M | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1192245557 CA378526874 |
356 | G>R | No |
ClinGen gnomAD |
|
|
CA213922383 rs978567792 |
358 | G>E | No |
ClinGen TOPMed gnomAD |
|
|
rs1431880172 CA378526887 |
358 | G>R | No |
ClinGen TOPMed gnomAD |
|
|
rs1264366886 CA378526896 |
359 | T>M | No |
ClinGen TOPMed |
|
|
CA378526892 rs1461141189 |
359 | T>S | No |
ClinGen TOPMed |
|
|
CA5690006 rs764058140 |
360 | P>R | No |
ClinGen ExAC gnomAD |
|
|
rs1315199629 CA378526904 |
361 | A>T | No |
ClinGen TOPMed |
|
|
rs1181047464 CA378526910 |
362 | A>S | No |
ClinGen gnomAD |
|
|
rs1283596786 CA378526925 |
364 | P>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed |
|
CA378526924 rs1283596786 |
364 | P>R | No |
ClinGen TOPMed |
|
|
rs1403588144 CA378526927 CA378526926 |
365 | G>R | No |
ClinGen TOPMed gnomAD |
|
|
rs1403588144 CA378526928 |
365 | G>W | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed gnomAD |
|
rs761715536 CA5690008 |
366 | E>* | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs761715536 CA213922384 |
366 | E>K | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA378526940 rs1293903882 |
367 | E>K | No |
ClinGen gnomAD |
|
|
CA213922385 rs538147682 |
368 | R>S | No |
ClinGen 1000Genomes gnomAD |
|
|
CA5690010 rs749945302 |
369 | V>F | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA378526951 rs749945302 |
369 | V>I | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs987438394 CA213922386 |
370 | G>A | No |
ClinGen TOPMed gnomAD |
|
|
rs987438394 CA378526959 |
370 | G>E | No |
ClinGen TOPMed gnomAD |
|
|
rs1344114233 CA378526957 |
370 | G>R | No |
ClinGen TOPMed |
|
| TCGA novel | 371 | A>D | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1401906980 CA378526966 |
371 | A>V | No |
ClinGen TOPMed |
|
|
rs1208158283 CA378526969 |
372 | A>S | No |
ClinGen gnomAD |
|
|
rs1257205653 CA378526990 |
375 | S>* | No |
ClinGen gnomAD |
|
|
rs755773499 CA378526996 |
376 | R>H | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA gnomAD |
|
rs755773499 CA5690011 |
376 | R>L | No |
ClinGen ExAC gnomAD |
|
|
CA378527008 rs1259408196 |
378 | R>C | No |
ClinGen gnomAD |
|
|
rs1444409992 CA378527011 |
378 | R>P | No |
ClinGen TOPMed |
|
|
CA5690013 rs754163723 |
379 | G>R | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1589532215 CA378527029 |
381 | Q>H | No |
ClinGen Ensembl |
|
|
CA378527037 rs1178358696 |
382 | N>K | No |
ClinGen gnomAD |
|
|
rs370313798 CA213922387 |
383 | R>G | No |
ClinGen ESP gnomAD |
|
|
rs748646629 CA5690016 |
383 | R>H | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA TOPMed gnomAD |
|
rs1800036 CA5690017 |
384 | E>* | No |
ClinGen ExAC gnomAD |
|
|
CA378527048 rs1391463412 |
384 | E>D | No |
ClinGen gnomAD |
|
|
CA378527044 rs1800036 |
384 | E>K | No |
ClinGen ExAC gnomAD |
|
|
rs201475397 CA5690018 |
385 | K>N | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
CA378527060 rs1589532234 |
386 | R>P | No |
ClinGen Ensembl |
|
|
CA378527059 rs1325613025 |
386 | R>S | No |
ClinGen gnomAD |
|
|
CA213922389 rs566971712 |
389 | F>L | No |
ClinGen gnomAD |
|
|
CA5690019 rs375454021 |
390 | V>M | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ESP ExAC NCI-TCGA TOPMed gnomAD |
|
rs771143397 CA5690020 |
392 | A>V | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA TOPMed gnomAD |
|
CA5690021 rs776995550 |
393 | V>L | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA gnomAD |
|
rs749035912 CA5690022 |
395 | I>V | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs768559743 CA5690023 |
396 | G>R | No |
ClinGen ExAC gnomAD |
|
|
CA378527136 rs373130841 |
399 | V>L | No |
ClinGen ESP TOPMed gnomAD |
|
|
rs373130841 CA213922390 |
399 | V>M | No |
ClinGen ESP TOPMed gnomAD |
|
|
CA378527140 rs1564745896 |
400 | V>M | No |
ClinGen Ensembl |
|
|
rs767408029 CA5690026 |
401 | C>S | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 403 | F>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1212565310 CA378527173 |
404 | P>H | No |
ClinGen TOPMed |
|
|
rs148162881 CA5690029 |
412 | T>M | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
CA5690030 rs765952169 |
414 | V>I | No |
ClinGen ExAC gnomAD |
|
|
CA378527293 rs35658213 |
416 | C>G | No |
ClinGen Ensembl |
|
|
VAR_055908 rs35658213 CA213922391 |
416 | C>S | No |
ClinGen UniProt Ensembl dbSNP |
|
|
CA5690032 rs754689304 |
417 | S>C | No |
ClinGen ExAC gnomAD |
|
|
rs1285869860 CA378527331 |
419 | P>A | No |
ClinGen gnomAD |
|
|
rs778172898 CA5690036 |
422 | L>R | No |
ClinGen ExAC |
|
|
rs1228876922 CA378527382 |
423 | F>C | No |
ClinGen gnomAD |
|
|
rs866925537 CA213922392 |
424 | K>R | No |
ClinGen Ensembl |
|
| TCGA novel | 427 | F>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA5690039 rs747042142 |
428 | W>C | No |
ClinGen ExAC gnomAD |
|
|
rs1303740549 CA378527472 |
429 | F>V | No |
ClinGen gnomAD |
|
|
CA213922393 rs143027701 |
431 | Y>* | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
| TCGA novel | 431 | Y>C | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA213922394 rs77286801 |
432 | C>F | No |
ClinGen ESP ExAC gnomAD |
|
|
CA5690041 rs77286801 |
432 | C>Y | No |
ClinGen ESP ExAC gnomAD |
|
|
rs1589532286 CA378527534 |
433 | N>K | No |
ClinGen Ensembl |
|
|
CA378527546 rs1589532289 |
434 | S>N | No |
ClinGen Ensembl |
|
|
CA5690042 rs746085432 |
435 | S>W | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1187558087 CA378527562 |
436 | L>W | No |
ClinGen TOPMed |
|
|
rs1355733199 CA378527589 |
438 | P>L | No |
ClinGen gnomAD |
|
|
rs1589532302 CA378527599 |
439 | V>G | No |
ClinGen Ensembl |
|
|
rs747921161 CA5690046 |
443 | I>V | No |
ClinGen ExAC gnomAD |
|
|
CA378527686 CA378527688 rs1407490897 |
446 | H>Q | No |
ClinGen TOPMed gnomAD |
|
|
rs773030170 CA5690049 |
446 | H>R | No |
ClinGen ExAC TOPMed |
|
|
rs1220313640 CA378527708 |
448 | F>L | No |
ClinGen TOPMed |
|
|
rs1350155054 CA378527724 |
449 | R>C | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
rs765866331 CA5690051 |
449 | R>H | No |
ClinGen ExAC gnomAD |
|
|
rs1351738795 CA378527736 |
450 | R>C | No |
ClinGen gnomAD |
|
|
rs759161719 CA5690053 |
450 | R>P | No |
ClinGen ExAC |
|
|
rs764891418 CA5690054 |
451 | A>T | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA gnomAD |
|
rs1343127063 CA378527750 |
451 | A>V | No |
ClinGen TOPMed |
|
|
rs753064524 CA5690055 |
453 | K>R | No |
ClinGen ExAC gnomAD |
|
|
rs763230238 CA5690056 |
455 | I>S | No |
ClinGen ExAC gnomAD |
|
|
CA5690058 rs751998895 |
457 | C>Y | No |
ClinGen ExAC gnomAD |
|
|
CA5690062 rs369219397 |
458 | R>L | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
rs369219397 CA5690061 |
458 | R>Q | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
CA378527843 rs547631131 |
459 | G>E | No |
ClinGen TOPMed |
|
|
rs547631131 CA213922399 |
459 | G>V | No |
ClinGen TOPMed |
|
|
CA378527846 rs950647547 |
460 | D>H | No |
ClinGen gnomAD |
|
|
CA213922400 rs950647547 |
460 | D>N | No |
ClinGen gnomAD |
|
|
rs1171770091 CA378527854 |
460 | D>V | No |
ClinGen TOPMed |
|
|
CA378527848 rs950647547 |
460 | D>Y | No |
ClinGen gnomAD |
|
|
rs1474044554 CA378527874 |
462 | K>E | No |
ClinGen gnomAD |
|
|
CA5690065 rs780174433 |
463 | R>Q | No |
ClinGen ExAC gnomAD |
|
|
CA5690064 rs756360648 |
463 | R>W | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA213922401 rs1006150720 |
465 | V>E | No |
ClinGen Ensembl |
|
|
CA5690066 rs747913823 |
465 | V>L | No |
ClinGen ExAC TOPMed gnomAD |
No associated diseases with P08913
12 GO annotations of cellular component
| Name | Definition |
|---|---|
| axon terminus | Terminal inflated portion of the axon, containing the specialized apparatus necessary to release neurotransmitters. The axon terminus is considered to be the whole region of thickening and the terminal button is a specialized region of it. |
| basolateral plasma membrane | The region of the plasma membrane that includes the basal end and sides of the cell. Often used in reference to animal polarized epithelial membranes, where the basal membrane is the part attached to the extracellular matrix, or in plant cells, where the basal membrane is defined with respect to the zygotic axis. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| dopaminergic synapse | A synapse that uses dopamine as a neurotransmitter. |
| GABA-ergic synapse | A synapse that uses GABA as a neurotransmitter. These synapses are typically inhibitory. |
| glutamatergic synapse | A synapse that uses glutamate as a neurotransmitter. |
| integral component of plasma membrane | The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| integral component of postsynaptic density membrane | The component of the postsynaptic density membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| integral component of presynaptic active zone membrane | The component of the presynaptic active zone membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| neuronal cell body | The portion of a neuron that includes the nucleus, but excludes cell projections such as axons and dendrites. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
| receptor complex | Any protein complex that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
11 GO annotations of molecular function
| Name | Definition |
|---|---|
| alpha-1B adrenergic receptor binding | Binding to an alpha-1B adrenergic receptor. |
| alpha-2C adrenergic receptor binding | Binding to an alpha-2C adrenergic receptor. |
| alpha2-adrenergic receptor activity | Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of alpha2-adrenergic receptors; the activity involves transmitting the signal to the Gi alpha subunit of a heterotrimeric G protein. |
| epinephrine binding | Binding to epinephrine, a hormone produced by the medulla of the adrenal glands that increases heart activity, improves the power and prolongs the action of muscles, and increases the rate and depth of breathing. It is synthesized by the methylation of norepinephrine. |
| G protein-coupled receptor activity | Combining with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. |
| heterotrimeric G-protein binding | Binding to a heterotrimeric G-protein. |
| norepinephrine binding | Binding to norepinephrine, (3,4-dihydroxyphenyl-2-aminoethanol), a hormone secreted by the adrenal medulla and a neurotransmitter in the sympathetic peripheral nervous system and in some tracts of the CNS. It is also the biosynthetic precursor of epinephrine. |
| protein heterodimerization activity | Binding to a nonidentical protein to form a heterodimer. |
| protein homodimerization activity | Binding to an identical protein to form a homodimer. |
| protein kinase binding | Binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate. |
| thioesterase binding | Binding to a thioesterase. |
43 GO annotations of biological process
| Name | Definition |
|---|---|
| actin cytoskeleton organization | A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins. |
| activation of protein kinase activity | Any process that initiates the activity of an inactive protein kinase. |
| activation of protein kinase B activity | Any process that initiates the activity of the inactive enzyme protein kinase B. |
| acute inflammatory response | Inflammation which comprises a rapid, short-lived, relatively uniform response to acute injury or antigenic challenge and is characterized by accumulations of fluid, plasma proteins, and granulocytic leukocytes. An acute inflammatory response occurs within a matter of minutes or hours, and either resolves within a few days or becomes a chronic inflammatory response. |
| adenylate cyclase-activating adrenergic receptor signaling pathway | An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process. |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of adenylyl cyclase activity and a subsequent increase in the intracellular concentration of cyclic AMP (cAMP). |
| adenylate cyclase-inhibiting adrenergic receptor signaling pathway | An adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor, and ending with the regulation of a downstream cellular process. |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the inhibition of adenylyl cyclase activity and a subsequent decrease in the intracellular concentration of cyclic AMP (cAMP). |
| adrenergic receptor signaling pathway | A G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process. |
| cellular response to hormone stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hormone stimulus. |
| DNA replication | The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognized and bound by initiation proteins, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA. |
| fear response | The response of an organism to a perceived external threat. |
| female pregnancy | The set of physiological processes that allow an embryo or foetus to develop within the body of a female animal. It covers the time from fertilization of a female ovum by a male spermatozoon until birth. |
| G protein-coupled receptor signaling pathway | The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane. |
| glucose homeostasis | Any process involved in the maintenance of an internal steady state of glucose within an organism or cell. |
| intestinal absorption | Any process in which nutrients are taken up from the contents of the intestine. |
| negative regulation of calcium ion transmembrane transporter activity | Any process that stops, prevents or reduces the frequency, rate or extent of calcium ion transmembrane transporter activity. |
| negative regulation of calcium ion transport | Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| negative regulation of calcium ion-dependent exocytosis | Any process that stops, prevents, or reduces the frequency, rate or extent of calcium ion-dependent exocytosis. |
| negative regulation of epinephrine secretion | Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of epinephrine. |
| negative regulation of insulin secretion | Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of insulin. |
| negative regulation of insulin secretion involved in cellular response to glucose stimulus | Any process that decreases the frequency, rate or extent of the regulated release of insulin that contributes to the response of a cell to glucose. |
| negative regulation of lipid catabolic process | Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids. |
| negative regulation of norepinephrine secretion | Any process that decreases the frequency, rate or extent of the regulated release of norepinephrine. |
| negative regulation of uterine smooth muscle contraction | Any process that decreases the frequency, rate or extent of uterine smooth muscle contraction. |
| phospholipase C-activating adrenergic receptor signaling pathway | A phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by ligand binding to an adrenergic receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| platelet activation | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug. |
| positive regulation of cell migration | Any process that activates or increases the frequency, rate or extent of cell migration. |
| positive regulation of cell population proliferation | Any process that activates or increases the rate or extent of cell proliferation. |
| positive regulation of cytokine production | Any process that activates or increases the frequency, rate or extent of production of a cytokine. |
| positive regulation of epidermal growth factor-activated receptor activity | Any process that activates or increases the frequency, rate or extent of EGF-activated receptor activity. |
| positive regulation of MAP kinase activity | Any process that activates or increases the frequency, rate or extent of MAP kinase activity. |
| positive regulation of MAPK cascade | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade. |
| positive regulation of membrane protein ectodomain proteolysis | Any process that activates or increases the frequency, rate or extent of membrane protein ectodomain peptidolysis. |
| positive regulation of potassium ion transport | Any process that activates or increases the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| positive regulation of wound healing | Any process that increases the rate, frequency, or extent of the series of events that restore integrity to a damaged tissue, following an injury. |
| Ras protein signal transduction | The series of molecular signals within the cell that are mediated by a member of the Ras superfamily of proteins switching to a GTP-bound active state. |
| receptor transactivation | The process in which a receptor is activated by another receptor. Receptor transactivation can occur through different mechanisms and includes cross-talk between signaling pathways where one receptor activates a receptor for a different ligand, and also activation of subunits within a receptor oligomer. |
| regulation of synaptic vesicle exocytosis | Any process that modulates the frequency, rate or extent of synaptic vesicle exocytosis. |
| regulation of vasoconstriction | Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels. |
| Rho protein signal transduction | The series of molecular signals within the cell that are mediated by a member of the Rho family of proteins switching to a GTP-bound active state. |
| thermoception | The series of events required for an organism to receive a temperature stimulus, convert it to a molecular signal, and recognize and characterize the signal. Thermoception in larger animals is mainly done in the skin; mammals have at least two types of sensor, for detecting heat (temperatures above body temperature) and cold (temperatures below body temperature). |
| vasodilation | An increase in the internal diameter of blood vessels, especially arterioles or capillaries, due to relaxation of smooth muscle cells that line the vessels, and usually resulting in a decrease in blood pressure. |
120 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q2YDN1 | GPR161 | G protein-coupled receptor 161 | Bos taurus (Bovine) | PR |
| Q0GBZ5 | HCRTR1 | Orexin/Hypocretin receptor type 1 | Bos taurus (Bovine) | PR |
| Q17QD8 | GPR37L1 | G-protein coupled receptor 37-like 1 | Bos taurus (Bovine) | PR |
| Q8SPN1 | PROKR2 | Prokineticin receptor 2 | Bos taurus (Bovine) | PR |
| P46626 | ADRB3 | Beta-3 adrenergic receptor | Bos taurus (Bovine) | PR |
| O46639 | TRHR | Thyrotropin-releasing hormone receptor | Bos taurus (Bovine) | PR |
| Q8SPN2 | PROKR1 | Prokineticin receptor 1 | Bos taurus (Bovine) | PR |
| B9VR26 | CMLKR1 | Chemerin-like receptor 1 | Bos taurus (Bovine) | PR |
| P18130 | ADRA1A | Alpha-1A adrenergic receptor | Bos taurus (Bovine) | PR |
| B4XF06 | GPR39 | G-protein coupled receptor 39 | Bos taurus (Bovine) | PR |
| Q28838 | ADRA2A | Alpha-2A adrenergic receptor | Bos taurus (Bovine) | PR |
| O18913 | OPN1LW | Long-wave-sensitive opsin 1 | Felis catus (Cat) (Felis silvestris catus) | PR |
| P28683 | PRA1 | Green-sensitive opsin | Gallus gallus (Chicken) | PR |
| Q9N298 | HTR1A | 5-hydroxytryptamine receptor 1A | Pan troglodytes (Chimpanzee) | PR |
| P08099 | Rh2 | Opsin Rh2 | Drosophila melanogaster (Fruit fly) | PR |
| P06002 | ninaE | Opsin Rh1 | Drosophila melanogaster (Fruit fly) | PR |
| Q4LBB9 | Octbeta2R | Octopamine receptor beta-2R | Drosophila melanogaster (Fruit fly) | PR |
| Q8NFJ6 | PROKR2 | Prokineticin receptor 2 | Homo sapiens (Human) | PR |
| Q13585 | GPR50 | Melatonin-related receptor | Homo sapiens (Human) | PR |
| Q9BZJ6 | GPR63 | Probable G-protein coupled receptor 63 | Homo sapiens (Human) | PR |
| Q9H3N8 | HRH4 | Histamine H4 receptor | Homo sapiens (Human) | PR |
| P28336 | NMBR | Neuromedin-B receptor | Homo sapiens (Human) | PR |
| Q9Y5Y3 | GPR45 | Probable G-protein coupled receptor 45 | Homo sapiens (Human) | PR |
| P41597 | CCR2 | C-C chemokine receptor type 2 | Homo sapiens (Human) | PR |
| P51681 | CCR5 | C-C chemokine receptor type 5 | Homo sapiens (Human) | PR |
| Q8TCW9 | PROKR1 | Prokineticin receptor 1 | Homo sapiens (Human) | PR |
| Q99788 | CMKLR1 | Chemerin-like receptor 1 | Homo sapiens (Human) | PR |
| P08908 | HTR1A | 5-hydroxytryptamine receptor 1A | Homo sapiens (Human) | PR |
| P30559 | OXTR | Oxytocin receptor | Homo sapiens (Human) | PR |
| P32239 | CCKBR | Gastrin/cholecystokinin type B receptor | Homo sapiens (Human) | PR |
| O60883 | GPR37L1 | G-protein coupled receptor 37-like 1 | Homo sapiens (Human) | PR |
| Q8TDU9 | RXFP4 | Relaxin-3 receptor 2 | Homo sapiens (Human) | PR |
| P04000 | OPN1LW | Long-wave-sensitive opsin 1 | Homo sapiens (Human) | PR |
| Q6U736 | OPN5 | Opsin-5 | Homo sapiens (Human) | PR |
| P34972 | CNR2 | Cannabinoid receptor 2 | Homo sapiens (Human) | PR |
| P24530 | EDNRB | Endothelin receptor type B | Homo sapiens (Human) | PR |
| Q6W5P4 | NPSR1 | Neuropeptide S receptor | Homo sapiens (Human) | PR |
| O43613 | HCRTR1 | Orexin/Hypocretin receptor type 1 | Homo sapiens (Human) | PR |
| P61073 | CXCR4 | C-X-C chemokine receptor type 4 | Homo sapiens (Human) | PR |
| Q9BXC0 | HCAR1 | Hydroxycarboxylic acid receptor 1 | Homo sapiens (Human) | PR |
| P30556 | AGTR1 | Type-1 angiotensin II receptor | Homo sapiens (Human) | PR |
| Q15761 | NPY5R | Neuropeptide Y receptor type 5 | Homo sapiens (Human) | PR |
| Q8N6U8 | GPR161 | G-protein coupled receptor 161 | Homo sapiens (Human) | PR |
| Q6DWJ6 | GPR139 | Probable G-protein coupled receptor 139 | Homo sapiens (Human) | PR |
| P21462 | FPR1 | fMet-Leu-Phe receptor | Homo sapiens (Human) | PR |
| P35414 | APLNR | Apelin receptor | Homo sapiens (Human) | PR |
| P46091 | CMKLR2 | Chemerin-like receptor 2 | Homo sapiens (Human) | PR |
| P32745 | SSTR3 | Somatostatin receptor type 3 | Homo sapiens (Human) | PR |
| P41439 | FOLR3 | Folate receptor gamma | Homo sapiens (Human) | PR |
| P35348 | ADRA1A | Alpha-1A adrenergic receptor | Homo sapiens (Human) | PR |
| P19973 | Lsp1 | Lymphocyte-specific protein 1 | Mus musculus (Mouse) | PR |
| O54799 | Nmbr | Neuromedin-B receptor | Mus musculus (Mouse) | PR |
| Q64264 | Htr1a | 5-hydroxytryptamine receptor 1A | Mus musculus (Mouse) | PR |
| P51675 | Ccr1 | C-C chemokine receptor type 1 | Mus musculus (Mouse) | PR |
| Q5U431 | Gpr39 | G-protein coupled receptor 39 | Mus musculus (Mouse) | PR |
| Q99JG2 | Gpr37l1 | G-protein coupled receptor 37-like 1 | Mus musculus (Mouse) | PR |
| P97295 | Npy2r | Neuropeptide Y receptor type 2 | Mus musculus (Mouse) | PR |
| O08786 | Cckar | Cholecystokinin receptor type A | Mus musculus (Mouse) | PR |
| P56481 | Cckbr | Gastrin/cholecystokinin type B receptor | Mus musculus (Mouse) | PR |
| P30731 | Gpr83 | G-protein coupled receptor 83 | Mus musculus (Mouse) | PR |
| P97468 | Cmklr1 | Chemerin-like receptor 1 | Mus musculus (Mouse) | PR |
| P21761 | Trhr | Thyrotropin-releasing hormone receptor | Mus musculus (Mouse) | PR |
| Q5QD16 | Taar3 | Trace amine-associated receptor 3 | Mus musculus (Mouse) | PR |
| P97292 | Hrh2 | Histamine H2 receptor | Mus musculus (Mouse) | PR |
| Q9EQQ3 | Gpr63 | Probable G-protein coupled receptor 63 | Mus musculus (Mouse) | PR |
| Q924H0 | Npffr2 | Neuropeptide FF receptor 2 | Mus musculus (Mouse) | PR |
| P34971 | Adrb1 | Beta-1 adrenergic receptor | Mus musculus (Mouse) | PR |
| Q91ZY2 | Hrh4 | Histamine H4 receptor | Mus musculus (Mouse) | PR |
| O88416 | Gpr33 | Probable G-protein coupled receptor 33 | Mus musculus (Mouse) | PR |
| Q8K087 | Cmklr2 | Chemerin-like receptor 2 | Mus musculus (Mouse) | PR |
| P70658 | Cxcr4 | C-X-C chemokine receptor type 4 | Mus musculus (Mouse) | PR |
| Q9WV08 | Aplnr | Apelin receptor | Mus musculus (Mouse) | PR |
| P97718 | Adra1a | Alpha-1A adrenergic receptor | Mus musculus (Mouse) | PR |
| Q8BZP8 | Npsr1 | Neuropeptide S receptor | Mus musculus (Mouse) | PR |
| Q8K458 | Prokr2 | Prokineticin receptor 2 | Mus musculus (Mouse) | PR |
| P58308 | Hcrtr2 | Orexin receptor type 2 | Mus musculus (Mouse) | PR |
| Q7TQP3 | Gpr119 | Glucose-dependent insulinotropic receptor | Mus musculus (Mouse) | PR |
| Q8BGE9 | Rxfp3 | Relaxin-3 receptor 1 | Mus musculus (Mouse) | PR |
| Q6VZZ7 | Opn5 | Opsin-5 | Mus musculus (Mouse) | PR |
| Q8CIM5 | Gpr84 | G-protein coupled receptor 84 | Mus musculus (Mouse) | PR |
| P25962 | Adrb3 | Beta-3 adrenergic receptor | Mus musculus (Mouse) | PR |
| Q80UC8 | Gpr139 | Probable G-protein coupled receptor 139 | Mus musculus (Mouse) | PR |
| P0C5I1 | Gpr25 | Probable G-protein coupled receptor 25 | Mus musculus (Mouse) | PR |
| P47936 | Cnr2 | Cannabinoid receptor 2 | Mus musculus (Mouse) | PR |
| Q5QD13 | Taar6 | Trace amine-associated receptor 6 | Mus musculus (Mouse) | PR |
| P35846 | Folr1 | Folate receptor alpha | Mus musculus (Mouse) | PR |
| P58307 | Hcrtr1 | Orexin/Hypocretin receptor type 1 | Mus musculus (Mouse) | PR |
| Q8C131 | Hcar1 | Hydroxycarboxylic acid receptor 1 | Mus musculus (Mouse) | PR |
| Q9EQQ4 | Gpr45 | Probable G-protein coupled receptor 45 | Mus musculus (Mouse) | PR |
| B2RPY5 | Gpr161 | G-protein coupled receptor 161 | Mus musculus (Mouse) | PR |
| Q764M9 | CXCR4 | C-X-C chemokine receptor type 4 | Sus scrofa (Pig) | PR |
| Q9EQD2 | Npffr2 | Neuropeptide FF receptor 2 | Rattus norvegicus (Rat) | PR |
| O08565 | Cxcr4 | C-X-C chemokine receptor type 4 | Rattus norvegicus (Rat) | PR |
| Q01717 | Trhr | Thyrotropin-releasing hormone receptor | Rattus norvegicus (Rat) | PR |
| P30936 | Sstr3 | Somatostatin receptor type 3 | Rattus norvegicus (Rat) | PR |
| Q9JHG3 | Aplnr | Apelin receptor | Rattus norvegicus (Rat) | PR |
| P43140 | Adra1a | Alpha-1A adrenergic receptor | Rattus norvegicus (Rat) | PR |
| P19327 | Htr1a | 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Rat) | PR |
| P56719 | Hcrtr2 | Orexin receptor type 2 | Rattus norvegicus (Rat) | PR |
| P28564 | Htr1b | 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Rat) | PR |
| P56718 | Hcrtr1 | Orexin/Hypocretin receptor type 1 | Rattus norvegicus (Rat) | PR |
| P28647 | Adora3 | Adenosine receptor A3 | Rattus norvegicus (Rat) | PR |
| P25102 | Hrh2 | Histamine H2 receptor | Rattus norvegicus (Rat) | PR |
| P23944 | Adra1d | Alpha-1D adrenergic receptor | Rattus norvegicus (Rat) | PR |
| Q8R415 | Prokr2 | Prokineticin receptor 2 | Rattus norvegicus (Rat) | PR |
| Q5QD24 | Taar3 | Trace amine-associated receptor 3 | Rattus norvegicus (Rat) | PR |
| P0C0W8 | Gpr139 | Probable G-protein coupled receptor 139 | Rattus norvegicus (Rat) | PR |
| P35370 | Oprl1 | Nociceptin receptor | Rattus norvegicus (Rat) | PR |
| P46090 | Cmklr2 | Chemerin-like receptor 2 | Rattus norvegicus (Rat) | PR |
| O97664 | CMKLR2 | Chemerin-like receptor 2 | Macaca mulatta (Rhesus macaque) | PR |
| O97666 | APLNR | Apelin receptor | Macaca mulatta (Rhesus macaque) | PR |
| Q56H79 | NPSR1 | Neuropeptide S receptor | Macaca mulatta (Rhesus macaque) | PR |
| Q18904 | npr-8 | Probable G-protein coupled receptor npr-8 | Caenorhabditis elegans | PR |
| Q09388 | gar-2 | Muscarinic acetylcholine receptor gar-2 | Caenorhabditis elegans | PR |
| B3DM66 | gpr161 | G-protein coupled receptor 161 | Xenopus tropicalis (Western clawed frog) (Silurana tropicalis) | PR |
| Q9W6A6 | opn1mw4 | Green-sensitive opsin-4 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| Q9W6A5 | opn1mw1 | Green-sensitive opsin-1 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| Q8AYM7 | opn1mw3 | Green-sensitive opsin-3 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| Q8AYN0 | opn1lw2 | Red-sensitive opsin-2 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| Q90X46 | gpr161 | G-protein coupled receptor 161 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MFRQEQPLAE | GSFAPMGSLQ | PDAGNASWNG | TEAPGGGARA | TPYSLQVTLT | LVCLAGLLML |
| 70 | 80 | 90 | 100 | 110 | 120 |
| LTVFGNVLVI | IAVFTSRALK | APQNLFLVSL | ASADILVATL | VIPFSLANEV | MGYWYFGKAW |
| 130 | 140 | 150 | 160 | 170 | 180 |
| CEIYLALDVL | FCTSSIVHLC | AISLDRYWSI | TQAIEYNLKR | TPRRIKAIII | TVWVISAVIS |
| 190 | 200 | 210 | 220 | 230 | 240 |
| FPPLISIEKK | GGGGGPQPAE | PRCEINDQKW | YVISSCIGSF | FAPCLIMILV | YVRIYQIAKR |
| 250 | 260 | 270 | 280 | 290 | 300 |
| RTRVPPSRRG | PDAVAAPPGG | TERRPNGLGP | ERSAGPGGAE | AEPLPTQLNG | APGEPAPAGP |
| 310 | 320 | 330 | 340 | 350 | 360 |
| RDTDALDLEE | SSSSDHAERP | PGPRRPERGP | RGKGKARASQ | VKPGDSLPRR | GPGATGIGTP |
| 370 | 380 | 390 | 400 | 410 | 420 |
| AAGPGEERVG | AAKASRWRGR | QNREKRFTFV | LAVVIGVFVV | CWFPFFFTYT | LTAVGCSVPR |
| 430 | 440 | 450 | 460 | ||
| TLFKFFFWFG | YCNSSLNPVI | YTIFNHDFRR | AFKKILCRGD | RKRIV |